These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28784626)

  • 1. Metabolic and endocrine connections of 17-hydroxypregnenolone in polycystic ovary syndrome women.
    de Medeiros SF; Ormond CM; de Medeiros MAS; de Souza Santos N; Banhara CR; Yamamoto MMW
    Endocr Connect; 2017 Oct; 6(7):479-488. PubMed ID: 28784626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the activity of the enzyme 11β-hydroxylase in the polycystic ovary syndrome.
    Freitas de Medeiros S; Angelo LCA; Souto de Medeiros MA; Barbosa BB; Yamamoto MMW
    Horm Mol Biol Clin Investig; 2020 Jan; 41(2):. PubMed ID: 31922957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X; Lin JF
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenal Androgen Predictive Effects on Clinical and Metabolic Abnormalities of Polycystic Ovary Syndrome.
    Medeiros SF; Barbosa BB; Medeiros MAS; Yamamoto AKLW; Yamamoto MMW
    Rev Bras Ginecol Obstet; 2022 Feb; 44(2):142-153. PubMed ID: 35213912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic disparities between obese and non-obese patients with polycystic ovary syndrome: implications for endometrial receptivity indicators.
    Li XL; Ji YF; Feng Y; Liu SW
    Gynecol Endocrinol; 2024 Dec; 40(1):2312895. PubMed ID: 38444321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Effects of Various Androgens on Polycystic Ovary Syndrome.
    de Medeiros SF; Barbosa BB; de Medeiros AKLWY; de Medeiros MAS; Yamamoto MMW
    Horm Metab Res; 2021 May; 53(5):341-349. PubMed ID: 33878788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of Biological Markers of Body Fat Distribution and Corticosteroidogenic Enzyme Activities in Women with Polycystic Ovary Syndrome.
    de Medeiros SF; de Medeiros MAS; Barbosa BB; Yamamoto MMW
    Horm Metab Res; 2019 Oct; 51(10):639-648. PubMed ID: 31578050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies?
    Meirow D; Raz I; Yossepowitch O; Brzezinski A; Rosler A; Schenker JG; Berry EM
    Hum Reprod; 1996 Sep; 11(9):1848-53. PubMed ID: 8921052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dehydroepiandrosterone sulfate/free androgen index ratio predicts a favorable metabolic profile in patients with polycystic ovary syndrome.
    Nadir A; Temizkan S; Ozderya A; Temizkan O; Orbay E; Aydin K
    Gynecol Endocrinol; 2019 Feb; 35(2):128-132. PubMed ID: 30324855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome.
    Anik Ilhan G; Yildizhan B; Pekin T
    Gynecol Endocrinol; 2019 Mar; 35(3):233-236. PubMed ID: 30303693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
    Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö
    J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients.
    Karadağ C; Yoldemir T; Gogas Yavuz D
    Gynecol Endocrinol; 2017 Mar; 33(3):234-237. PubMed ID: 27908213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Androgen Levels, Endocrine and Metabolic Indices, and Clinical Findings in Women with Polycystic Ovary Syndrome in Uygur and Han Ethnic Groups from Xinjiang Province in China.
    Zhao H; Song X; Zhang L; Xu Y; Wang X
    Med Sci Monit; 2018 Sep; 24():6774-6780. PubMed ID: 30252834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenal hyperandrogenism does not deteriorate insulin resistance and lipid profile in women with PCOS.
    Paschou SA; Palioura E; Ioannidis D; Anagnostis P; Panagiotakou A; Loi V; Karageorgos G; Goulis DG; Vryonidou A
    Endocr Connect; 2017 Nov; 6(8):601-606. PubMed ID: 28912337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism.
    Castelo-Branco C; Steinvarcel F; Osorio A; Ros C; Balasch J
    Gynecol Endocrinol; 2010 Oct; 26(10):736-42. PubMed ID: 20569105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Biochemical Profiles according to Homeostasis Model Assessment-insulin Resistance (HOMA-IR) in Korean Women with Polycystic Ovary Syndrome.
    Lee DE; Park SY; Park SY; Lee SR; Chung HW; Jeong K
    J Menopausal Med; 2014 Dec; 20(3):104-10. PubMed ID: 25580421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (PCOS) and women with non-classic congenital adrenal hyperplasia (NCAH).
    Chanukvadze D; Kristesashvili J; Kvashilava N
    Iran J Reprod Med; 2012 Jul; 10(4):307-14. PubMed ID: 25246891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary syndrome patients and normal cycling women.
    Medeiros SF; Barbosa JS; Yamamoto MM
    J Obstet Gynaecol Res; 2015 Feb; 41(2):254-63. PubMed ID: 25256274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.